Published in Int J Tuberc Lung Dis on August 03, 2012
A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol (2004) 42.68
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med (2011) 7.13
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet (2009) 6.96
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS (2006) 6.46
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS (2001) 5.61
Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 4.45
Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health (2010) 3.79
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis (2005) 2.91
Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS (2009) 2.86
Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr (2009) 2.77
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis (2011) 2.70
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA (2008) 2.45
Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc (2009) 2.44
Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis (2009) 2.25
Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 2.24
Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol (2000) 2.20
Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis (2006) 2.09
Interactions among drugs for HIV and opportunistic infections. N Engl J Med (2001) 2.08
Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS (2010) 1.99
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother (2006) 1.58
Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS (2009) 1.56
Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect (2005) 1.51
Tuberculosis and HIV infection: the global setting. J Infect Dis (2007) 1.50
Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS (2005) 1.39
Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis (2009) 1.30
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther (2005) 1.09
Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr (2008) 0.87
Gamma-tubulin is a centrosomal protein required for cell cycle-dependent microtubule nucleation. Nature (1992) 3.87
Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J (2013) 2.35
Counseling and testing TB patients for HIV: evaluation of three implementation models in Kinshasa, Congo. Int J Tuberc Lung Dis (2008) 1.60
False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis (2012) 1.47
Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J (1998) 1.32
Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis (2012) 1.08
Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis (2013) 1.03
Effects of anticoagulants and temperature on expression of activation markers CD11b and HLA-DR on human leukocytes. Clin Diagn Lab Immunol (1998) 0.95
Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. Eur J Clin Microbiol Infect Dis (2013) 0.90
Echinococcosis in sub-Saharan Africa: emerging complexity. Vet Parasitol (2011) 0.86
A cautionary note about estimating effects of secondary exposures in cohort studies. Am J Epidemiol (2015) 0.80
A systematic evaluation of bathophenanthroline, ferrozine and ferene in an ICSH-based method for the measurement of serum iron. Ann Clin Biochem (1989) 0.78
Estrogen plus estrogen receptor antagonists alter mineral production by osteoblasts in vitro. Horm Metab Res (2011) 0.78
Human papillomavirus types in HIV seropositive men with penile warts in Johannesburg, South Africa. Int J STD AIDS (2011) 0.78
A screening test for detecting iron overload in population studies. S Afr Med J (1988) 0.76
Hypophyseal-portal concentrations of growth hormone-releasing factor and somatostatin in conscious pigs: relationship to production of spontaneous growth hormone pulses. Proc Soc Exp Biol Med (1998) 0.76
Tree-Based Methods for Discovery of Association between Flow Cytometry Data and Clinical Endpoints. Adv Bioinformatics (2010) 0.75
Psychiatric disturbance with acute onset and offset in a Darwin evacuee. Med J Aust (1975) 0.75
Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste. S Afr Med J (2022) 0.75
Deciding when to institute terminal palliative care for AIDS patients--an evidence-based approach. S Afr Med J (2001) 0.75
Sisonke phase 3B open-label study: Lessons learnt for national and global vaccination scale-up during epidemics. S Afr Med J (2021) 0.75
Periappendiceal hydatidosis: an unusual cause of right iliac fossa pain. Br J Surg (1994) 0.75
Transferrin iron interactions with cultured hepatocellular carcinoma cells (PLC/PRF/5). Eur J Cell Biol (1988) 0.75
Malaria pigment and extracellular iron. Possible target for iron chelating agents. Biochem Pharmacol (1993) 0.75
Effect of alpha-difluoromethylornithine on L-phenylalanine mustard-induced cytotoxicity and DNA interstrand cross-linking in a human cell line in vitro. Cancer Res (1986) 0.75
The effect of single-density bovine serum albumin columns on sperm concentration, motility, and morphology. Fertil Steril (1983) 0.75
Albuquerque Target Cities: preliminary findings. J Psychoactive Drugs (1999) 0.75
Administration of a nonpeptidyl growth hormone secretagogue, L-163, 255, changes somatostatin pattern, but has no effect on patterns of growth hormone-releasing factor in the hypophyseal-portal circulation of the conscious pig. Proc Soc Exp Biol Med (1999) 0.75